Indisulam Exerts Anticancer Effects Via Modulation of Transcription, Translation and Alternative Splicing on Human Cervical Cancer Cells

Overview

Journal Am J Cancer Res

Specialty Oncology

Date 2023 Aug 10

PMID 37559979

Authors

Zhihui Dou

Xuetian Zhang

Wei Su

Taotao Zhang

Fei Ye

Dapeng Zhao

Xiaohua Chen

Qiang Li

Hong Zhang

Cuixia Di

Affiliations

Soon will be listed here.

Abstract

Indisulam is a synthetic sulfonamides drug with anticancer activity in various tumors. However, the effect and molecular mechanism of indisulam have still not been studied in human cervical cancer. We treated human cervical cancer cell lines (HeLa and C33A) with indisulam, evaluated its efficacy, and investigated its molecular targets. Indisulam inhibited tumor growth and induced RBM39 degradation in a dose-dependent manner. RNA-seq and proteomics analysis revealed that indisulam disrupted transcriptional regulation pathways related to mRNA splicing and apoptosis. More importantly, indisulam caused mis-splicing of RNA transcripts including p73 isoforms ΔNp73 and TAp73 which have opposite roles in apoptosis regulation. Indisulam increased TAp73 expression and triggered mitochondrial apoptosis independent of p53 status in HeLa cells. In summary, our data suggests that indisulam has therapeutic potential in cervical cancer, representing an attractive strategy in p53-disrupted cancers and should be further investigated.

Citing Articles

Recent advances in anticancer mechanisms of molecular glue degraders: focus on RBM39-dgrading synthetic sulfonamide such as indisulam, E7820, tasisulam, and chloroquinoxaline sulfonamide.

Jang J, Kim J, Lee T Genes Genomics. 2024; 46(12):1345-1361.

PMID: 39271535 DOI: 10.1007/s13258-024-01565-z.

References

Kiraz Y, Adan A, Yandim M, Baran Y . Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol. 2016; 37(7):8471-86. DOI: 10.1007/s13277-016-5035-9. View

Wang E, Lu S, Pastore A, Chen X, Imig J, Chun-Wei Lee S . Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell. 2019; 35(3):369-384.e7. PMC: 6424627. DOI: 10.1016/j.ccell.2019.01.010. View

Fukuoka K, Usuda J, Iwamoto Y, Fukumoto H, Nakamura T, Yoneda T . Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest New Drugs. 2001; 19(3):219-27. DOI: 10.1023/a:1010608317361. View

Owa T, Yoshino H, Okauchi T, Yoshimatsu K, Ozawa Y, Sugi N . Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J Med Chem. 1999; 42(19):3789-99. DOI: 10.1021/jm9902638. View

Xu Y, Nijhuis A, Keun H . RNA-binding motif protein 39 (RBM39): An emerging cancer target. Br J Pharmacol. 2020; 179(12):2795-2812. DOI: 10.1111/bph.15331. View

Liu M, Wang Z, Liu Q, Zhu H, Xu N . Expression of Micro-RNA-492 (MiR-492) in Human Cervical Cancer Cell Lines is Upregulated by Transfection with Wild-Type P53, Irradiation, and 5-Fluorouracil Treatment In Vitro. Med Sci Monit. 2018; 24:7750-7758. PMC: 6354641. DOI: 10.12659/MSM.911585. View

Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M . Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol. 2007; 3(9):570-5. DOI: 10.1038/nchembio.2007.16. View

Zhang Q, Di C, Yan J, Wang F, Qu T, Wang Y . Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells. Artif Cells Nanomed Biotechnol. 2019; 47(1):1273-1280. DOI: 10.1080/21691401.2019.1596922. View

van Kesteren C, Beijnen J, Schellens J . E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anticancer Drugs. 2002; 13(10):989-97. DOI: 10.1097/00001813-200211000-00002. View

10.

Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E . The Functional Impact of Alternative Splicing in Cancer. Cell Rep. 2017; 20(9):2215-2226. DOI: 10.1016/j.celrep.2017.08.012. View

11.

Bussiere D, Xie L, Srinivas H, Shu W, Burke A, Be C . Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nat Chem Biol. 2019; 16(1):15-23. DOI: 10.1038/s41589-019-0411-6. View

12.

Voss P, Wang J . Liquid-liquid phase separation: Galectin-3 in nuclear speckles and ribonucleoprotein complexes. Exp Cell Res. 2023; 427(1):113571. PMC: 10199649. DOI: 10.1016/j.yexcr.2023.113571. View

13.

Huang S, Hao D, Zhang Y, Liu H, Shan W . Progress in studies of the mechanisms and clinical diagnosis of cervical carcinoma associated with genomic integration of high-risk human papillomavirus DNA. Yi Chuan. 2017; 39(9):775-783. DOI: 10.16288/j.yczz.17-151. View

14.

Ramos H, Raimundo L, Saraiva L . p73: From the p53 shadow to a major pharmacological target in anticancer therapy. Pharmacol Res. 2020; 162:105245. DOI: 10.1016/j.phrs.2020.105245. View

15.

Franca Vieira E Silva F, Padin-Iruegas M, Caponio V, Lorenzo-Pouso A, Saavedra-Nieves P, Chamorro-Petronacci C . Caspase 3 and Cleaved Caspase 3 Expression in Tumorogenesis and Its Correlations with Prognosis in Head and Neck Cancer: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2022; 23(19). PMC: 9569947. DOI: 10.3390/ijms231911937. View

16.

OKeefe R, Mayeda A, Sadowski C, Krainer A, Spector D . Disruption of pre-mRNA splicing in vivo results in reorganization of splicing factors. J Cell Biol. 1994; 124(3):249-60. PMC: 2119927. DOI: 10.1083/jcb.124.3.249. View

17.

Punt C, Fumoleau P, van de Walle B, Faber M, Ravic M, Campone M . Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol. 2001; 12(9):1289-93. DOI: 10.1023/a:1012287111922. View

18.

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

19.

Ting T, Goralski M, Klein K, Wang B, Kim J, Xie Y . Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15. Cell Rep. 2019; 29(6):1499-1510.e6. PMC: 7950731. DOI: 10.1016/j.celrep.2019.09.079. View

20.

Carneiro B, El-Deiry W . Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17(7):395-417. PMC: 8211386. DOI: 10.1038/s41571-020-0341-y. View